VivoSeq
Other

Stage III

7

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Stage III is an early-stage landscape with 7 programs across 7 companies. The most active players are Eastern Cooperative Oncology Group, Pfizer, Bayer. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

25/100

Attrition Rate

60/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

2 programs

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule343%
Protein / enzyme229%
Monoclonal antibody114%
Antibody–drug conjugate114%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

10

clinical trials

Terminated6 · 60%
Completed2 · 20%
Unknown status1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03907488·994 enrolled
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
Completed·UUniversity of Washington·Phase 1·NCT00005023
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT01902173·27 enrolled
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
Terminated·SWOG Cancer Research Network·Phase 2·NCT00002921·13 enrolled
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Terminated·SWOG Cancer Research Network·Phase 2·NCT00002735·68 enrolled
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Terminated·PPharmatech·Phase 2·NCT00766246·125 enrolled
Patiromer Trial in CKD Stage IIIB to V
Terminated·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 3·NCT05786469·2 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
Terminated·UUniversity of Miami·N/A·NCT00772668·3 enrolled
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Terminated·NRG Oncology·Phase 3·NCT02200042·1 enrolled
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC
Unknown status·SShaare Zedek Medical Center·Phase 2·NCT02824952·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)